Notably in our AngII model, TG2 inhibitor 1–155 had no effect on systolic hypertension or heart rate when compared to the mice receiving AngII alone, indicating that TG2 inhibitor 1–155 was acting directly to prevent cardiac fibrosis in vivo, and not via a secondary change in blood pressure. This evidence concerns the gene TGM2 and hypertensive disorder.